In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
Improved mood and mental clarity (11-14% of reviews) A subset of the energy-improvement group specifically mentions mood elevation, reduced anxiety, or "mental sharpness." This aligns with B12's role in neurotransmitter synthesis and methylation reactions affecting serotonin and dopamine pathways (Kennedy, Nutrients , 2016)
Janine Magnesium View product Excellent customer service
Insufficiency of regulatory T cells (Treg) and regulatory B cells (Breg), imbalance between Th17-lymphocytes and Treg-lymphocytes, abnormal production of pro-inflammatory cytokines has a significant influence on the progression of AITD
[PubMed: 36907786] 257
GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes
